CN108289833B - 用于递送囊封剂的稳定的已组装纳米结构 - Google Patents
用于递送囊封剂的稳定的已组装纳米结构 Download PDFInfo
- Publication number
- CN108289833B CN108289833B CN201680066453.1A CN201680066453A CN108289833B CN 108289833 B CN108289833 B CN 108289833B CN 201680066453 A CN201680066453 A CN 201680066453A CN 108289833 B CN108289833 B CN 108289833B
- Authority
- CN
- China
- Prior art keywords
- composition
- particles
- organogel
- hydrogel
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 39
- 239000008393 encapsulating agent Substances 0.000 title description 8
- 239000000203 mixture Substances 0.000 claims abstract description 123
- 239000003381 stabilizer Substances 0.000 claims abstract description 67
- 239000000017 hydrogel Substances 0.000 claims abstract description 34
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 31
- 239000000032 diagnostic agent Substances 0.000 claims abstract description 22
- 229940039227 diagnostic agent Drugs 0.000 claims abstract description 22
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 22
- 239000002245 particle Substances 0.000 claims description 142
- 239000000499 gel Substances 0.000 claims description 78
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 48
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 47
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 47
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 47
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 44
- 229960003668 docetaxel Drugs 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 30
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 235000012000 cholesterol Nutrition 0.000 claims description 24
- 229940107161 cholesterol Drugs 0.000 claims description 24
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims description 23
- IQUCNXSZNHPPML-UHFFFAOYSA-N 2-chloro-n-[(4-chlorophenyl)-phenylmethyl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C(NC(=O)CCl)C1=CC=CC=C1 IQUCNXSZNHPPML-UHFFFAOYSA-N 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 19
- -1 ascorbyl decanoate Chemical compound 0.000 claims description 18
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 17
- 239000002953 phosphate buffered saline Substances 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 229930182558 Sterol Natural products 0.000 claims description 13
- 239000000835 fiber Substances 0.000 claims description 13
- 150000003432 sterols Chemical class 0.000 claims description 13
- 235000003702 sterols Nutrition 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 150000003904 phospholipids Chemical class 0.000 claims description 12
- 229940127089 cytotoxic agent Drugs 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 102000004506 Blood Proteins Human genes 0.000 claims description 9
- 108010017384 Blood Proteins Proteins 0.000 claims description 9
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 7
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 6
- 238000009825 accumulation Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 5
- 229950005143 sitosterol Drugs 0.000 claims description 5
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 5
- 238000000527 sonication Methods 0.000 claims description 5
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 229960004544 cortisone Drugs 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000007704 transition Effects 0.000 claims description 4
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 claims description 3
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 claims description 3
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 claims description 3
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 claims description 3
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 claims description 3
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 claims description 3
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 claims description 3
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 claims description 3
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 claims description 3
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 claims description 3
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 claims description 3
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims description 3
- JPBAVLUULZJFFO-JENHRLMUSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O JPBAVLUULZJFFO-JENHRLMUSA-N 0.000 claims description 3
- DWKSHXDVQRZSII-SUMWQHHRSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DWKSHXDVQRZSII-SUMWQHHRSA-N 0.000 claims description 3
- MSKSZMDNKAEBSG-HNAYVOBHSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O MSKSZMDNKAEBSG-HNAYVOBHSA-N 0.000 claims description 3
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 claims description 3
- 235000019416 cholic acid Nutrition 0.000 claims description 3
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 3
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 claims description 3
- 229940058690 lanosterol Drugs 0.000 claims description 3
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- 235000015500 sitosterol Nutrition 0.000 claims description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 2
- OSELKOCHBMDKEJ-UHFFFAOYSA-N (10R)-3c-Hydroxy-10r.13c-dimethyl-17c-((R)-1-methyl-4-isopropyl-hexen-(4c)-yl)-(8cH.9tH.14tH)-Delta5-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 OSELKOCHBMDKEJ-UHFFFAOYSA-N 0.000 claims description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 claims description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 2
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 claims description 2
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 claims description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- CQSRUKJFZKVYCY-UHFFFAOYSA-N 5alpha-isofucostan-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(=CC)C(C)C)C1(C)CC2 CQSRUKJFZKVYCY-UHFFFAOYSA-N 0.000 claims description 2
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 claims description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 2
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 claims description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 2
- 239000004380 Cholic acid Substances 0.000 claims description 2
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 claims description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 2
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 claims description 2
- GBBBJSKVBYJMBG-QTWVXCTBSA-N Fucosterol Natural products CC=C(CC[C@@H](C)[C@@H]1CC[C@@H]2[C@H]3C=C[C@@H]4C[C@H](O)CC[C@@]4(C)[C@@H]3CC[C@@]12C)C(C)C GBBBJSKVBYJMBG-QTWVXCTBSA-N 0.000 claims description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 2
- OSELKOCHBMDKEJ-VRUYXKNBSA-N Isofucosterol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C OSELKOCHBMDKEJ-VRUYXKNBSA-N 0.000 claims description 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims description 2
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 claims description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002478 aldosterone Drugs 0.000 claims description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 claims description 2
- 229940061641 androsterone Drugs 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 229940076810 beta sitosterol Drugs 0.000 claims description 2
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 claims description 2
- 235000004420 brassicasterol Nutrition 0.000 claims description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 2
- 235000000431 campesterol Nutrition 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 2
- 229960002471 cholic acid Drugs 0.000 claims description 2
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims description 2
- 229960003290 cortisone acetate Drugs 0.000 claims description 2
- ZESRJSPZRDMNHY-UHFFFAOYSA-N de-oxy corticosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 ZESRJSPZRDMNHY-UHFFFAOYSA-N 0.000 claims description 2
- 229940119740 deoxycorticosterone Drugs 0.000 claims description 2
- 229960002061 ergocalciferol Drugs 0.000 claims description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 2
- 229960001348 estriol Drugs 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 229960003399 estrone Drugs 0.000 claims description 2
- OSELKOCHBMDKEJ-JUGJNGJRSA-N fucosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC\C(=C/C)C(C)C)[C@@]1(C)CC2 OSELKOCHBMDKEJ-JUGJNGJRSA-N 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 claims description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims description 2
- 229940068065 phytosterols Drugs 0.000 claims description 2
- 229960003387 progesterone Drugs 0.000 claims description 2
- 239000000186 progesterone Substances 0.000 claims description 2
- 230000010069 protein adhesion Effects 0.000 claims description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 2
- 229940032091 stigmasterol Drugs 0.000 claims description 2
- 235000016831 stigmasterol Nutrition 0.000 claims description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 229960003604 testosterone Drugs 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000001892 vitamin D2 Nutrition 0.000 claims description 2
- 239000011653 vitamin D2 Substances 0.000 claims description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 2
- 235000005282 vitamin D3 Nutrition 0.000 claims description 2
- 239000011647 vitamin D3 Substances 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 229940021056 vitamin d3 Drugs 0.000 claims description 2
- 235000021472 generally recognized as safe Nutrition 0.000 claims 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 69
- 102000004190 Enzymes Human genes 0.000 abstract description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 7
- 230000004044 response Effects 0.000 abstract description 5
- 238000013270 controlled release Methods 0.000 abstract description 4
- 230000001687 destabilization Effects 0.000 abstract description 2
- 230000001976 improved effect Effects 0.000 abstract description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 54
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 24
- 230000002776 aggregation Effects 0.000 description 24
- 238000004220 aggregation Methods 0.000 description 24
- 239000001587 sorbitan monostearate Substances 0.000 description 24
- 235000011076 sorbitan monostearate Nutrition 0.000 description 24
- 229940035048 sorbitan monostearate Drugs 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 239000011718 vitamin C Substances 0.000 description 23
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 22
- 229930003268 Vitamin C Natural products 0.000 description 22
- 235000019154 vitamin C Nutrition 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 21
- 239000013543 active substance Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 238000009472 formulation Methods 0.000 description 18
- 230000002209 hydrophobic effect Effects 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 238000001338 self-assembly Methods 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 239000005720 sucrose Substances 0.000 description 11
- 239000010432 diamond Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000005538 encapsulation Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000002105 nanoparticle Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000012669 liquid formulation Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 239000002121 nanofiber Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229910021642 ultra pure water Inorganic materials 0.000 description 6
- 239000012498 ultrapure water Substances 0.000 description 6
- 108090000371 Esterases Proteins 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 238000001879 gelation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000004626 scanning electron microscopy Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010007979 Glycocholic Acid Proteins 0.000 description 3
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 229960005420 etoposide Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000007863 gel particle Substances 0.000 description 3
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 3
- 229940099347 glycocholic acid Drugs 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 239000002091 nanocage Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 150000004713 phosphodiesters Chemical class 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 3
- 229960001796 sunitinib Drugs 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 2
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 2
- NENOAJSZZPODGJ-OIMNJJJWSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octanoate Chemical compound CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NENOAJSZZPODGJ-OIMNJJJWSA-N 0.000 description 2
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 2
- UEYVMVXJVDAGBB-ZHBLIPIOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl tetradecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O UEYVMVXJVDAGBB-ZHBLIPIOSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- JVXZRNYCRFIEGV-UHFFFAOYSA-M dilC18(3) dye Chemical compound [O-]Cl(=O)(=O)=O.CC1(C)C2=CC=CC=C2N(CCCCCCCCCCCCCCCCCC)C1=CC=CC1=[N+](CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2C1(C)C JVXZRNYCRFIEGV-UHFFFAOYSA-M 0.000 description 2
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 229960003685 imatinib mesylate Drugs 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 2
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 229960000371 rofecoxib Drugs 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- 238000005549 size reduction Methods 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 229950006451 sorbitan laurate Drugs 0.000 description 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 2
- 229950004959 sorbitan oleate Drugs 0.000 description 2
- 229950001248 squalamine Drugs 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- SVHIJLOAVJCJNN-GULOHRGCSA-N (6z,10r)-3,6,10-trimethyl-5,8,9,10-tetrahydrobenzo[8]annulen-2-ol Chemical compound C[C@@H]1CC\C=C(C)/CC2=CC(C)=C(O)C=C12 SVHIJLOAVJCJNN-GULOHRGCSA-N 0.000 description 1
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JNGRENQDBKMCCR-UHFFFAOYSA-N 2-(3-amino-6-iminoxanthen-9-yl)benzoic acid;hydrochloride Chemical compound [Cl-].C=12C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O JNGRENQDBKMCCR-UHFFFAOYSA-N 0.000 description 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical class NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
- LUCHPKXVUGJYGU-UHFFFAOYSA-N 4-amino-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one Chemical compound O=C1N=C(N)C(C)=CN1C1OC(CO)C(O)C1 LUCHPKXVUGJYGU-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100031655 Cytochrome b5 Human genes 0.000 description 1
- 108010007167 Cytochromes b5 Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- RMUYEULWFKIJCI-UHFFFAOYSA-N Parvifolin Natural products CC1(C)CCC(O)C23COC(O)(C(O)C12)C45CC(CC(O)C34)C(C)(O)C5=O RMUYEULWFKIJCI-UHFFFAOYSA-N 0.000 description 1
- SVHIJLOAVJCJNN-UHFFFAOYSA-N Parvifoline Natural products CC1CCC=C(C)CC2=CC(C)=C(O)C=C12 SVHIJLOAVJCJNN-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- JHSNLCCMZMGXLK-UHFFFAOYSA-N [3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-hydroxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COCC(O)COCC(O)CO JHSNLCCMZMGXLK-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- WPBUPFBTCDYKNM-UHFFFAOYSA-M [6-(diethylamino)-9-(2-octadecoxycarbonylphenyl)xanthen-3-ylidene]-diethylazanium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C21 WPBUPFBTCDYKNM-UHFFFAOYSA-M 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- KQNZLOUWXSAZGD-UHFFFAOYSA-N benzylperoxymethylbenzene Chemical compound C=1C=CC=CC=1COOCC1=CC=CC=C1 KQNZLOUWXSAZGD-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 239000002812 cholic acid derivative Substances 0.000 description 1
- 150000001842 cholic acids Chemical class 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001553 co-assembly Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 1
- 229960005073 erlotinib hydrochloride Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical class CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
描述具有血清稳定性的非共价组装的水凝胶或有机凝胶组合物。低分子量(<2,500Da)的一般视为安全(GRAS)的物质在稳定剂存在下以适当的摩尔百分比组装,形成具有纳米结构的水凝胶或有机凝胶,该等纳米结构在血清中抵挡拆解或去稳定一段经延长的时间段。该组合物用以递送一种或多种治疗剂、预防剂或诊断剂,使得回应于生物刺激物如酶而控制释放并且使得给药功效得到极大改进。
Description
技术领域
所公开技术一般处于采用低分子量的已组装纳米结构的药物递送领域中。
关于联邦资助研究或开发的声明
本发明在政府支持下在由美国国家卫生研究院(National InstitutesofHealth)授予的授权号R21DE023432下进行。政府对本发明拥有一定的权利。
相关申请的交叉引用
本申请要求2015年10月8日提交的美国临时申请第62/239,211号的权益,该申请特此以全文引用的方式并入本文中。
背景技术
形成以分子形式定义的高度有序的结构的自组装在很大程度上依赖于非共价相互作用。在组装过程期间由自组装形成的结构能够将分子包覆在溶液中,产生适用于递送疏水剂及亲水剂的可注射载剂。
然而,自组装结构一般不稳定并且经受生物、化学及机械扰动。举例来说,自组装结构与血液蛋白质的相互作用是多样和复杂的,经常对已组装结构的稳定性和体内行为有严重影响。血清脂蛋白可藉由扰动已组装结构的疏水性-亲水性相互作用而使两亲构筑嵌段去稳定。已组装结构中的相边界处的不规律性可促进去稳定效应。(Bonte F和JulianoRL,《类脂化学与物理学(Chemistry andPhysics ofLipids)》,40:359-372(1986))。破坏已组装结构经常导致内含物损失和治疗性递送失败。
使用自组装结构回应于病理环境的控制释放给出重大挑战。药物递送***从给药点到达目标组织的能力会受多种屏障的限制。举例来说,口服给药的药物递送***必须穿过胃中的酸,以跨肠上皮被吸收,并且避免肝脏清除和非特异性吸收。全身性给予的自组装物质受到在血液蛋白质下去稳定、负荷损失和从循环中快速清除的挑战。
因此,本发明的一个目标是提供一般用视为安全的物质形成的稳定的自组装水凝胶或有机凝胶。
本发明的另一个目标是提供回应于生物刺激物控制释放的稳定自组装载剂。
本发明的又一目标是提供一种在给药功效增加并且较低毒性的情况下将活性剂递送到疾病部位的方法。
发明内容
包括胶凝因子和非胶凝因子两亲物的凝胶可共组装以形成凝胶。这些凝胶具有纳米和微米形态,例如在扫描电子显微术(“SEM”)下纤维通常是遍及数百纳米和数十到数百微米长。这些可被加工成保留纳米结构的颗粒。凝胶和凝胶颗粒适用于递送治疗剂、预防剂和/或诊断剂。已开发出血液稳定的自组装水凝胶或有机凝胶组合物。在稳定剂存在下,一般视为安全(GRAS)或药学上可接受的低分子量(<2,500Da)胶凝因子以适当的摩尔百分比组装成水凝胶或有机凝胶。组装产生纳米级结构,如薄层、胶束、囊泡和纤维,形成水凝胶或有机凝胶的结构基础。在37℃下在含血清蛋白的磷酸盐缓冲盐水存在下,使用稳定剂,组合物可维持其至少50%、60%、70%或80%的尺寸或更大,和/或不聚集到为暴露于血清蛋白至少30分钟之前的原始尺寸的两倍。不同于无稳定剂的处于适当的摩尔百分比(或摩尔分数)下的组合物,水凝胶/有机凝胶组合物在全身性循环中持续更长时间,持续至少一小时、两小时、四小时、十二小时或24小时。稳定剂对水凝胶/有机凝胶的已组装纳米结构赋予硬度并且增加其充填密度,由此防止或减缓由已组装纳米结构的血液蛋白质造成的破坏。稳定剂可与胶凝因子共组装,或并入或夹入形成的纳米结构中。稳定剂也可包覆于已组装纳米结构中。
胶凝因子一般是低分子量GRAS化合物,药学上可接受的或前药,其回应于生物刺激物如酶、pH和温度而不稳定,并且一般能够作为活性剂释放。合适的胶凝因子包括烷酸抗坏血酸酯、脱水山梨糖醇烷酸酯、三甘油单烷酸酯、蔗糖烷酸酯、甘胆酸和其组合。例示性烷酸抗坏血酸酯包括棕榈酸抗坏血酸酯、癸酸抗坏血酸酯、月桂酸抗坏血酸酯、辛酸抗坏血酸酯、肉豆蔻酸抗坏血酸酯和油酸抗坏血酸酯,其是可水解或酶可裂解的以释放抗坏血酸,即维生素C。优选的胶凝因子是棕榈酸抗坏血酸酯。例示性脱水山梨糖醇烷酸酯包括脱水山梨糖醇单硬脂酸酯、脱水山梨糖醇癸酸酯、脱水山梨糖醇月桂酸酯、脱水山梨糖醇辛酸酯、脱水山梨糖醇肉豆蔻酸酯和脱水山梨糖醇油酸酯。例示性三甘油单烷酸酯包括三甘油单棕榈酸酯、三甘油单癸酸酯、三甘油单月桂酸酯、三甘油单辛酸酯、三甘油单肉豆蔻酸酯、三甘油单硬脂酸酯和三甘油单油酸酯。例示性蔗糖烷酸酯包括蔗糖棕榈酸酯、蔗糖癸酸酯、蔗糖月桂酸酯、蔗糖辛酸酯、蔗糖肉豆蔻酸酯和蔗糖油酸酯。
为赋予血液稳定性,已组装凝胶组合物中稳定剂的适当摩尔百分比是至少5摩尔%、10摩尔%、15摩尔%、20摩尔%、25摩尔%或30摩尔%,其中在血液中组合物的尺寸持续至少30分钟、1小时、2小时或4小时地保持至少50%、60%、70%或80%或更大。合适的稳定剂包括固醇、磷脂和低分子量治疗剂、预防剂或诊断剂。作为稳定剂,例示性固醇是约10摩尔%、20摩尔%或30摩尔%的胆固醇。作为稳定剂,例示性磷脂是约30摩尔%、40摩尔%或45摩尔%的二棕榈酰基磷脂酰基甘油。另一例示性稳定剂是约5摩尔%、6摩尔%、7摩尔%、8摩尔%、9摩尔%、10摩尔%、11摩尔%或12摩尔%的化学治疗性多西他赛(docetaxel)。
在组装过程期间,一种或多种治疗剂、预防剂或诊断剂可通过囊封进一步包括于组合物中。虽然呈自由形式的溶液中的药剂可具有较差治疗功效或无治疗功效,但基于所公开的前药或GRAS化合物的已组装凝胶一般展现增强的治疗功效。举例来说,在抑制4T3鼠乳癌中,基于棕榈酸抗坏血酸酯的已组装组合物具有约40μM-60μM的半数最大抑制浓度(IC50),然而在此浓度范围内的抗坏血酸溶液可能不具有治疗功效。在组合物中使用前药或GRAS胶凝因子,所包括的治疗剂、预防剂或诊断剂经常展现增强作用,其中与独自施用的治疗剂、预防剂或诊断剂相比,针对治疗益处需要低得多的剂量。举例来说,当以基于棕榈酸抗坏血酸酯的已组装组合物形式递送时,化学治疗药物多西他赛具有增强的抗癌作用。可能因增强型渗透和滞留(EPR)作用所致,具有纳米结构的组合物可优先在肿瘤中积累。与在不存在已组装组合物下递送的药剂相比较,相较于肝脏,组合物一般在肿瘤中具有更大分配。
血液稳定的自组装水凝胶或有机凝胶组合物可与药学上可接受的赋形剂组合给予。其还可按剂量单位形式以试剂盒形式供应,其中无水组分和液体组分单独地含有并在针对原位胶凝在向个体给药时混合。
也已开发出制备血液稳定的自组装水凝胶或有机凝胶组合物的方法。首先将胶凝因子、稳定剂和任选的待囊封剂溶解于适当溶剂中,如溶解于二甲亚砜(DMSO)、甲醇、乙醇、己烷、异丙醇和水中。将该物质加热到适当温度,在60℃-80℃范围外或范围内直至完全溶解,随后冷却到约室温。随后添加一定量的水,例如超纯水,并且将该物质加热到适当温度直至完全溶解。胶凝一般在约15分钟-45分钟后发生。可将凝胶悬浮于超纯水中并且再悬浮于超纯水中并且经过脉冲超声处理。
块体凝胶包括至少部分的具有纳米结构形态的物质。块体凝胶可断裂成凝胶颗粒。凝胶形态保留在颗粒中。粒度和聚集可用作稳定性的度量。目标不是尺寸显著减小,也不是聚集(即,尺寸增加)。颗粒通常具有不规律形态并且经常看起来像纤维。
组合物可用以向个体递送治疗剂、预防剂或诊断剂而用于控制释放。这些可通过静脉内注射、输注、局部和植入而全身性给药。
附图说明
图1A是显示形成具有纤维形态的块体凝胶的GRAS两亲物的自组装的示意图。图1B是概述呈块体凝胶和来源于其的颗粒形式的纳米结构的共自组装(co-selfassembly)的示意图。图1C是显示从块体凝胶提取颗粒的示意图。
图2A-图2D是概述血清稳定剂在GRAS凝胶中共自组装和囊封以获得血清稳定颗粒的示意图:2A,胶凝和自组装;2B,将胆固醇并入纳米结构中;2C,范围磷脂并入纳米结构中;和2D,多西他赛的并入。
图3是显示在添加于血清中后颗粒的流体动力学直径(nm)随时间(小时)推移的线图。
图4是相较于酯酶(200u/ml)(正方形),PBS(菱形)中累积释放%随时间(小时)推移的图式。
图5A是针对以摩尔比7:3组装有棕榈酸抗坏血酸酯(AP)和胆固醇的颗粒(正方形);以8:2的摩尔比组装有AP和Chol的颗粒(菱形);以9:1的摩尔比组装有AP和Chol的颗粒(三角形);和仅组装有AP的颗粒(x),在添加血清后,流体动力学直径(nm)随时间(小时)推移的图式。图5B是显示在添加血清后颗粒的流体动力学直径(nm)随时间(小时)推移的线图:以6:4的摩尔比组装有AP和二棕榈酰基磷脂酰基甘油(DPPG)的颗粒(正方形);以7:3的摩尔比组装有AP和二棕榈酰基磷脂酰基甘油(DPPG)的颗粒(三角形);以8:2的摩尔比组装有AP和二棕榈酰基磷脂酰基甘油(DPPG)的颗粒(菱形);和组装有AP的颗粒(x)。图5C是显示在添加于血清中后颗粒的流体动力学直径(nm)随时间(小时)推移的线图:以9.2:0.8的摩尔比组装有AP和多西他赛(DTX)的颗粒(正方形);以9.6:0.4的摩尔比组装有AP和多西他赛(DTX)的颗粒(菱形);以9.2:0.8的摩尔比组装有AP和多西他赛(DTX)的颗粒(正方形);和组装有AP的颗粒(x)。
图6A和6B是流体动力学直径(nm)随时间(小时)推移的图式,其显示胆固醇(Chol)充当三甘油单硬脂酸酯(TG-18)颗粒的稳定剂,并且有助于防止其在50%血清中在37℃下聚集。TG-18颗粒不同于AP颗粒,其往往会在血清中聚集,导致其尺寸随时间推移而增加。这一聚集通过添加40摩尔%的胆固醇来防止。不同时间点下血清中TG-18颗粒的尺寸(正方形);和不同时间点下血清中TG-18:Chol::6:4颗粒的尺寸(菱形)。图6B是图式
图6C是显示多西他赛(DTX)不使三甘油单硬脂酸酯(TG-18)颗粒稳定、并且不有助于防止其在50%血清中在37℃下聚集的图式。TG-18颗粒不同于AP颗粒,其往往会在血清中聚集,导致其尺寸随时间推移而增加。这一聚集不会通过添加8摩尔%的DTX得到防止。不同时间点下血清中TG-18颗粒的尺寸(正方形);和不同时间点下血清中TG-18:DTX::9.2:0.8颗粒的尺寸(菱形)。
图7A是流体动力学直径(nm)随时间(小时)推移的图式,其显示胆固醇(Chol)部分地使脱水山梨糖醇单硬脂酸酯(SMS)颗粒在50%血清中在37℃下稳定。在血清中SMS颗粒往往会显示即刻的拆解,导致其尺寸急剧并且快速地减小,并且这随后是其聚集,导致其尺寸随时间推移而增加。不同点下血清中SMS颗粒的尺寸(菱形)。在时间t=0下,SMS颗粒的尺寸从585nm(PBS中的尺寸)降到160nm,指示其在血清中拆解。随后,由于聚集,尺寸增加。SMS:Chol::6:4颗粒的尺寸由正方形所显示。结果指示添加40摩尔%的chol防止最初的拆解但不防止后续的聚集。
图7B是显示DPPG部分地使脱水山梨糖醇单硬脂酸酯(SMS)颗粒在50%血清中在37℃下稳定的图式。在血清中SMS颗粒往往会显示即刻的拆解,导致其尺寸急剧并且快速地减小,并且这随后是其聚集,导致其尺寸随时间推移而增加。不同点下血清中SMS颗粒的尺寸(菱形)。在时间t=0下,SMS颗粒的尺寸从585nm(PBS中的尺寸)降到160nm,指示其在血清中拆解。
随后,由于聚集,尺寸增加。SMS:DPG::6:4颗粒的尺寸(正方形)。结果指示添加40摩尔%的DPPG防止最初的拆解但不防止后续的聚集。
图8A是显示以下的代谢活性%的线图:用一系列浓度(μM)的维生素C溶液培育48小时(“Vit C 48h”,黑色正方形)、或用稳定的维生素C衍生颗粒培育24小时或48小时(分别是“Vit C颗粒24h”(灰色正方形)和“Vit C颗粒48h”(三角形))的PC3(PC-3)人类***癌细胞。图8B是显示以下的代谢活性%的线图:用Vit C培育48小时(黑色方形)、用Vit C颗粒培育24小时(灰色方形)和用Vit C颗粒培育48小时(三角形)的LNCaP雄激素敏感性人类***腺癌细胞。
图9A和图9B是显示当用一系列浓度(μM)的稳定的维生素C衍生颗粒(“Vit C颗粒”,灰色方形)、自由多西他赛(“自由DTX”,菱形)或囊封多西他赛的稳定的维生素C衍生颗粒(“DTX负载的Vit C颗粒”,三角形)培育时,PC3细胞的代谢活性%(图9A)和LNCaP细胞的代谢活性%(图9B)的线图。
图10是显示对于对照(未处理)小鼠和给予自由染料或囊封该染料的稳定的维生素C衍生颗粒的小鼠,在给药后3小时、8小时和12小时,小鼠肿瘤组织中染料(DiR)的归一化荧光随时间(小时)推移的条形图。
图11A和图11B是显示患有乳癌的小鼠中呈自由形式的给药后染料或负载于稳定的维生素C衍生颗粒中的给药后染料的组织分布的条形图。图11A显示不同组织中染料的荧光强度。图11B显示肿瘤中的荧光与肝脏中的荧光的比率。
具体实施方式
I.定义
术语“胶凝因子”是指在一种或多种溶剂中可通过非共价相互作用自组装的分子,该等非共价相互作用如氢键结、范德华力(van der Waals)相互作用、疏水性相互作用、离子相互作用、pi-pi叠加或其组合。胶凝因子可通过经由例如毛细管力固定溶剂而形成凝胶。胶凝因子可包括水胶凝因子(例如,形成水凝胶的胶凝因子)和有机胶凝因子(例如,形成有机凝胶的胶凝因子)。在一些实施例中,胶凝因子可形成水凝胶和有机凝胶两者。
术语“自组装”是指分子在合适的环境中自发组装或组织以形成高度有序的结构如水凝胶或有机凝胶的能力。
术语“水凝胶”是指通常共价(例如,聚合物水凝胶)或非共价(例如,自组装水凝胶)地保持在一起的分子的3D网络,其中水是主要组分(通常大于80%)。凝胶可通过胶凝因子的自组装或通过胶凝因子的化学交联而形成。基于水的胶凝因子可用以形成水凝胶,然而有机胶凝因子是在有机溶剂为主要组分的溶剂中形成凝胶(有机凝胶(organogel/organo-gel))的胶凝因子。
术语“有机凝胶”是指通常共价(例如,聚合物水凝胶)或非共价(例如,自组装水凝胶)地保持在一起的分子的3D网络,其中有机溶剂是主要组分(通常大于80%)。凝胶可通过胶凝因子的自组装或通过胶凝因子的化学交联而形成。
术语“治疗剂”是指可给予以预防或治疗疾病或病症或功能障碍的一种或多种症状的药剂。
术语“诊断剂”一般是指可出于鉴别或成像的目的给予的药剂。
术语“预防剂”一般是指可给予以预防疾病或预防类似妊娠的某些病状的药剂。
术语“前药”是指在体内或原位转化成其治疗活性或可用形式之前不完全具活性或可用的药物、改性药物的药物前体。
“血液”是指在动物内循环以递送养分和气体的细胞悬浮液以及其中的细胞。“血清”是在血液凝结后剩余的液体,并且纤维蛋白凝块和细胞物质被去除。“血浆”是血液的非细胞组分。血液、血浆和血清的蛋白含量是不同的,但对于所有这三种,大多数蛋白质是共同的。
II.组合物
1.胶凝因子
胶凝因子是自组装以形成具有纳米纤维结构的凝胶组合物的两亲分子。在一个优选实施例中,这些是GRAS物质,分子量一般小于2,500Da。
在一些实施例中,GRAS胶凝因子可包括烷酸抗坏血酸酯、脱水山梨糖醇烷酸酯、三甘油单烷酸酯、蔗糖烷酸酯、甘胆酸或其任何组合。烷酸酯可包括通过不稳定键(例如,酯键、氨基甲酸酯键、硫酯键和酰胺键)键结到抗坏血酸基、脱水山梨糖醇、三甘油或蔗糖分子的疏水性C1-C22烷基(例如,乙酰基、乙基、丙基、丁基、戊基、辛酰基、羊脂基、月桂基、肉豆蔻基、软脂酰基、硬脂酰基、花生基或山嵛基)。举例来说,烷酸抗坏血酸酯可包括棕榈酸抗坏血酸酯、癸酸抗坏血酸酯、月桂酸抗坏血酸酯、辛酸抗坏血酸酯、肉豆蔻酸抗坏血酸酯、油酸抗坏血酸酯或其任何组合。脱水山梨糖醇烷酸酯可包括脱水山梨糖醇单硬脂酸酯、脱水山梨糖醇癸酸酯、脱水山梨糖醇月桂酸酯、脱水山梨糖醇辛酸酯、脱水山梨糖醇肉豆蔻酸酯、脱水山梨糖醇油酸酯或其任何组合。三甘油单烷酸酯可包括三甘油单棕榈酸酯、三甘油单癸酸酯、三甘油单月桂酸酯、三甘油单辛酸酯、三甘油单肉豆蔻酸酯、三甘油单硬脂酸酯、三甘油单油酸酯或其任何组合。蔗糖烷酸酯可包括蔗糖棕榈酸酯、蔗糖癸酸酯、蔗糖月桂酸酯、蔗糖辛酸酯、蔗糖肉豆蔻酸酯、蔗糖油酸酯或其任何组合。在一些实施例中,GRAS胶凝因子包括棕榈酸抗坏血酸酯、脱水山梨糖醇单硬脂酸酯、三甘油单棕榈酸酯、蔗糖棕榈酸酯或甘胆酸。
代表性的低分子量GRAS胶凝因子包括维生素前体,如棕榈酸抗坏血酸酯(维生素C前体)、乙酸视黄酯(维生素一种前体)和α-生育酚乙酸酯(维生素E前体)。
在一些实施例中,替代或补充GRAS第一胶凝因子,自组装凝胶组合物可由包括2,500或更小的分子量的两亲3-氨基苯甲酰胺衍生物形成。胶凝因子也可以是在生理条件下可转成药物的活性形式的前药或包括该前药。
在其它实施例中,一个或多个具有C1到C30基团的饱和或不饱和烃链通过酯化或氨基甲酸酯键、酐键和/或酰胺键以合成方式改性成低分子量的一般亲水性化合物。范围C1到C30包括C1、C2、C3、C4、C5、C6、C7、C8、C9、C10、C11、C12、C13、C14、C15、C16、C17、C18、C19等到C30,以及属于C1到C30内的范围,例如C1到C29、C2到C30、C3到C28等。
在一些实施例中,α生育酚乙酸酯、乙酸视黄酯、棕榈酸视黄酯或其组合可与胶凝因子共组装。
2.可降解键
因给药部位处或期望释放的地方例如肿瘤或感染区域处的特征所致,可存在唤起刺激释放(Stimuli evoking release)。这些可为存在于血液或血清中的条件,或存在于细胞、组织或器官内部或外部的条件。凝胶组合物可被设计成仅在存在于细胞、组织或器官的疾病病况(例如发炎)中的条件下拆解,如此使得药剂在靶向组织和/或器官处释放。
举例来说,凝胶组合物可包括在与酶接触时可裂解和/或可通过水解来裂解的可降解键,如酯键、酰胺键、酐键、硫酯键和氨基甲酸酯键。通常,键始终在两亲分子的亲水性部分与疏水性部分之间。在一些实施例中,基于磷酸酯的键可通过磷酸酶裂解。在一些实施例中,不稳定键是氧化还原可裂解的并且在还原或氧化时裂解(例如,-S-S-)。在一些实施例中,可降解键对温度敏感,例如可在高温下裂解,例如可在37℃-100℃、40℃-100℃、45℃-100℃、50℃-100℃、60℃-100℃、70℃-100℃的温度范围内裂解。在一些实施例中,可降解键可在生理温度(例如,36℃到40℃、约36℃、约37℃、约38℃、约39℃、约40℃)下裂解。举例来说,键可通过温度增加而裂解。这可允许使用更低剂量,因为药剂仅在所需部位处释放。另一益处是降低对其它器官和组织的毒性。在某些实施例中,刺激可以是超声、温度、pH、金属离子、光、电刺激、电磁刺激和其组合。
3.稳定剂
在给药后增强血液稳定性和/或减少纳米结构的拆解速率的试剂包括于组合物中。包括白蛋白的血液蛋白质可与已组装薄层状、胶束、囊状和/或纤维结构中的不规律性(如相边界处存在的那些不规律性)相互作用,导致颗粒或更高级结构化纳米颗粒或块体水凝胶的拆解速率更高。稳定剂通常对已组装结构赋予硬度,增加其充填密度和/或增强其强度,如此改变相转变过程和转变温度,和/或调节已组装颗粒的表面特性以减少或防止蛋白质粘着或积聚。
一般来说,当置于血清溶液中时稳定剂减弱已组装颗粒或纳米颗粒的尺寸的减小速率,然而无稳定剂的组合物大体上在约30分钟内减小血清溶液中的流体动力学尺寸。稳定剂允许多于50%、60%、70%、80%、90%、95%、99%的已组装纳米结构在37℃下与血清一起培育时,在至少一小时、两小时、三小时、四小时、12小时、24小时或48小时内,在流体动力学尺寸方面具有小于1%、5%、10%、15%、20%或30%的减小。
一般来说,可固定自组装薄层的分子将通常是疏水性分子、类似小链亲水性聚合物的可改变表面特性的分子和/或可改变表面电荷的分子(带电荷分子)。
在一些实施例中,在形成已组装凝胶组合物中,稳定剂与胶凝因子共组装。这些稳定剂一般通过囊封、整合、包覆、***或夹入而并入薄层状、胶束、囊状和/或纤维结构中。一般来说,包括10摩尔%-30摩尔%的共组装类型,稳定剂使得已组装纳米颗粒当在血清溶液中在两小时到四小时的时段内培育时维持约80%或更大的原始尺寸。
例示性稳定剂包括固醇、磷脂和通常是疏水性的低分子量治疗化合物。合适的固醇包括胆固醇、皮质类固醇如二氢胆固醇、羊毛固醇、β-谷固醇、菜油固醇、豆固醇、菜籽固醇、ergocasterol、维生素D、植物固醇、谷固醇、醛固酮、雄酮、睾酮、***、麦角钙化醇、麦角固醇、***-17α、***-17β、胆酸、皮质酮、雌三醇、羊毛固醇、石胆酸、孕酮、胆钙化醇、皮质醇、可的松(cortisone)、乙酸可的松、乙酸皮质醇、脱氧皮质酮和雌酮以及岩藻固醇。其它稳定剂包括但不限于溶血磷脂(包括溶血PC、2-己癸氧基-氧离子基-磷酰基)氧基乙基-三甲基-铵);神经节苷脂,包括GM1和GT1b、硫苷脂;鞘磷酯;合成糖磷脂(glycopholipid),如唾液酸-乳糖基酰基(sialo-lactosyl);磷脂,包括DOPE、DOPS、POPE、DPPE、DSPE;亲脂性药物,如阿糖胞苷二磷酸二脂酰甘油;蛋白质如细胞色素b5、人类高密度脂蛋白(HDL)、人类血型糖蛋白A;短链亲水性聚合物,包括聚乙二醇(PEG)和其与脂质的衍生物;胆酸,包括牛磺胆酸、脱氧胆酸和geicocholic酸;1,1'-双十八基3,3,3',3'-四甲基-吲哚羰花青过氯酸盐(DiI);DiR;DiD;异硫氰酸荧光素;异硫氰酸四甲基罗丹明(tetramethylrhodamine isothiocyanate);罗丹明B十八基酯过氯酸盐和N'-十八基荧光素-5-硫脲。固醇一般与一种或多种胶凝因子共组装,***有序的薄层状、胶束、囊状和/或纤维结构中。通过自身的固醇不是胶凝因子并且本身不能形成凝胶组合物。
合适的磷脂包括二棕榈酰基磷脂酰基胆碱和二硬脂酰基磷脂酰基胆碱。在形成有序的薄层状和/或纤维结构中,磷脂通常与一种或多种胶凝因子共组装。
在其它实施例中,稳定剂是囊封于已组装组合物中的试剂,其通常在整个凝胶组合物中,而非***或夹入薄层状、胶束、囊状和/或纤维结构中。一般来说,包括5摩尔%与15摩尔%之间的稳定剂使得已组装纳米结构当在血清溶液中在两小时到四小时的时段内培育时维持约80%或更大的原始尺寸。
在一些实施例中,当置于血液或血清溶液中时,治疗剂、预防剂和/或诊断剂可减弱已组装纳米颗粒的尺寸减小,其中相较于无活性剂的凝胶组合物,多于50%、60%、70%、80%、90%、95%、99%的纳米结构在37℃下在与血清一起培育时,在至少一小时、两小时、三小时、四小时、12小时、24小时或48小时内,在流体动力学尺寸方面具有小于1%、5%、10%、15%、20%或30%的减小。当以2%、4%、6%、8%和10%的摩尔百分比(并且所有值在范围内)在活性剂与胶凝因子之间囊封时,一种例示性的疏水性化学治疗剂多西他赛可使由胶凝因子形成的纳米结构稳定。
用作凝胶组合物的稳定剂的合适的低分子量治疗剂、预防剂和/或诊断剂一般是疏水性的,具有低分子量(例如,小于2,500Da),如多西他赛和类固醇以及其它疏水剂如***(dexamethasone),或药剂的组合。
4.治疗剂、预防剂和诊断剂
已组装凝胶组合物可用以向有需要的个人或个体递送一种或多种治疗剂、预防剂或诊断剂。治疗剂、预防剂和诊断剂可以是蛋白质、肽、糖或多糖、脂质或脂蛋白或脂多糖、核酸(DNA、RNA、siRNA、miRNA、tRNA、piRNA等)或小分子(通常2000D或更小,更通常1000D或更小,有机、无机、天然或合成的)。
胶凝因子可以是以水解或酶方式降解并且释放活性剂的前药。治疗剂、预防剂或诊断剂可经过物理包覆、囊封,或与凝胶组合物的纳米纤维结构非共价地缔合。治疗剂、预防剂或诊断剂可用一种或多种胶凝因子、一种或多种稳定剂共价修饰,或用作胶凝因子。替代地,其并入凝胶组合物的已组装有序的薄层状、囊泡和/或纳米纤维结构中或定位于已组装结构的表面上。
已组装纳米结构也可用以共递送多种药剂,由此产生其协同或添加效应并且一般导致所需的治疗功效剂量较少。协同性可通过以下方式实现:将活性剂囊封于基于前药的颗粒中,例如用包括维生素C、维生素K和其衍生物的胶凝因子制备的颗粒;通过共包覆多种药剂,通过共递送其它敏化分子或其组合。
疏水剂和亲水剂均可按高囊封和负载效率囊封于这些颗粒中,并且在普通生理条件下稳定地囊封。囊封剂可包括例如消炎药、类固醇、抗生素、免疫抑止剂、化学治疗剂、敏化剂、抗体、抗体片段、蛋白质、肽、生长因子、细胞因子、细胞、干细胞、核酸、siRNA、维生素等和其组合。
例示性治疗剂和预防剂包括蛋白质或肽、糖或多糖、脂质、核酸或其组合。在一个优选实施例中,这些是小分子,一般具有2000道尔顿或更小、更优选1000道尔顿或更小的分子量。治疗剂的例示性类别包括但不限于抗增生剂如抗癌剂、抗血管生成剂和抗有丝***剂、镇痛剂、消炎药、退热剂、抗癫痫剂、抗精神病剂(antiopsychotic agent)、神经保护剂、抗传染剂如抗细菌剂、抗病毒剂和抗真菌剂、抗组胺剂、抗偏头痛药、抗毒蕈碱药、抗焦虑药、止痛药、***、抗精神病药(antipsychotics)、支气管扩张药、抗哮喘药、心脏血管药、皮质类固醇、多巴胺能剂、胃肠道药、肌肉松弛剂、拟副交感神经剂、刺激剂、减食欲剂和抗发作性睡病剂。
包括于蛋白质纳米笼中的优选的小分子类别包括癌症治疗剂,如化学治疗剂、细胞因子、趋化因子和放疗增强剂。大部分化学治疗药物可以分成:烷基化剂、抗代谢物、蒽环霉素、植物生物碱、拓扑异构酶抑制剂和其它抗肿瘤剂。所有这些药物以一定方式影响细胞***或DNA合成和功能。额外治疗剂包括单克隆抗体(包括其片段)和酪氨酸激酶抑制剂,例如甲磺酸伊马替尼(imatinib mesylate)(或),其直接靶向某些类型的癌症(慢性骨髓性白血病、胃肠道间质瘤)中的分子异常。
例示性治疗剂包括化学治疗剂和抗肿瘤剂。代表性的化学治疗剂包括但不限于多西他赛、小红莓(doxorubicin)、右雷佐生(dexrazoxane)、索拉非尼(sorafenib)、盐酸埃罗替尼(erlotinib hydrochloride)、含铂药物如顺铂(cisplatin)、西妥昔单抗(cetuximab)、舒尼替尼(sunitinib)、贝伐单抗(bevacizumab)、卡铂(carboplatin)、奥沙利铂(oxaliplatin)、氮芥(mechlorethamine)、环磷酰胺、苯丁酸氮芥(chlorambucil)、长春新碱(vincristine)、长春碱(vinblastine)、长春瑞宾(vinorelbine)、长春地辛(vindesine)、紫杉醇(taxol)和其衍生物、伊立替康(irinotecan)、拓朴替康(topotecan)、安吖啶(amsacrine)、依托泊苷(etoposide)、磷酸依托泊苷、替尼泊甙(teniposide)、表鬼臼毒素(epipodophyllotoxin)、曲妥珠单抗(trastuzumab)、利妥昔单抗(rituximab)和其组合。
在一些实施例中,药剂是一种或多种核酸。核酸可改变、纠正或代替内源性核酸序列。核酸用以治疗癌症,纠正影响粘液覆盖的组织的其它疾病和代谢疾病中的基因的缺陷,基因如用于治疗帕金森氏(Parkinson's)和ALS的那些基因,其中该等基因通过鼻递送到达脑。一个实例是(哌加他尼钠(pegaptanim sodium)、抗VEGF适体或EYEOOl)(眼科技医药公司(Eyetech Pharmaceuticals))。
基因疗法是用于纠正负责疾病开发的缺陷性基因的技术。存在数种用于纠正错误基因的途径。普通基因可***基因组内的非特定位置中以代替非功能基因。通过同源重组,异常基因可被普通基因调换。异常基因可通过选择性反向突变修复,此使基因恢复到其普通功能。可改变特定基因的调节(基因开启或关断的程度)。
核酸可以是DNA、RNA、化学修饰核酸或其组合。举例来说,用于增加核酸半衰期的稳定性和抗酶裂解性的方法是所属领域中已知的,并且可包括一种或多种对聚核苷酸的核碱基、糖或键的修饰或取代。核酸可定制合成以含有被调适成适于所需用途的特性。常见的修饰包括但不限于使用锁核酸(LNA)、解锁核酸(UNA)、吗啉核酸、肽核酸(PNA)、硫代磷酸酯键、膦酰乙酸酯键、丙炔类似物、2'-O-甲基RNA、5-Me-dC、2'-5'键联的磷酸二酯键、嵌合键(混合硫代磷酸酯和磷酸二酯键和修饰),与脂质和肽结合以及其组合。
在一些实施例中,核酸包括核苷酸间键修饰,如具有非手性和不带电亚基间键的磷酸酯类似物(例如,Sterchak,E.P.等人,《有机化学(Organic Chem.)》,52:4202,(1987)),或具有非手性亚基间键的基于吗啉基的不带电聚合物(参见例如美国专利第5,034,506号)。一些核苷酸间键类似物包括吗啉酸(morpholidate)、乙缩醛和聚酰胺键联的杂环。其它骨架和键修饰包括但不限于硫代磷酸酯、肽核酸、三环DNA、诱铒寡核苷酸、核酶、spiegelmer(含有L核酸,具有高结合亲和力的适体)或CpG寡聚物。
治疗性蛋白质、蛋白质片段、肽或相关化合物包括血管内皮生长因子(VEGF)的抗体,如贝伐单抗()和rhuFAb V2(兰比珠单抗(ranibizumab),)和其它抗VEGF化合物;色素上皮衍生因子(PEDF);干扰素α;白细胞介素-12(IL-12);内皮生长抑素;血管生长抑素;核糖核酸酶抑制剂,如(Sima Therapeutics);多功能抗血管生成剂,如(AE-941)(加拿大魁北克市的安特玛实验室(AetemaLaboratories,Quebec City,Canada));表皮生长因子受体的抗体,如帕尼单抗(panitumumab)()和西妥昔单抗()以及所属领域中已知的其它抗血管生成剂。
可递送的其它小分子包括COX-2抑制剂,如塞内昔布(celecoxib)()和罗非昔布(rofecoxib)();沙立度胺(thalidomide)()和其衍生物,如来那度胺(lenalidomide)();角鲨胺(squalamine););受体酪胺酸激酶(RTK)抑制剂,如舒尼替尼();酪氨酸激酶抑制剂,如索拉非尼()和埃罗替尼()。
例示性诊断材料包括顺磁性分子、荧光化合物、磁性分子和放射性核素。合适的诊断剂包括但不限于x射线成像剂和显影剂。放射性核素也可用作成像剂。
其他合适的造影剂的实例包括气体或气体散发化合物,其是不透射线的。蛋白质纳米笼可进一步包括适用于确定所给予纳米笼的位置的试剂。适用于这一目的的试剂包括荧光标签、放射性核素和造影剂。
5.配制物
液体配制物
液体配制物含有一种或多种悬浮于液体医药载剂中的已组装颗粒。
合适的液体载剂包括但不限于蒸馏水、去离子水、纯水或超纯水、盐水以及含有盐和/或缓冲剂的其它生理学上可接受的水溶液,如磷酸盐缓冲盐水(PBS)、林格氏溶液(Ringer's solution)和等张氯化钠,或可接受用于给予动物或人类的任何其它水溶液。
优选地,液体配制物相对于生理流体是等张的且具有大致相同的pH值,在约pH4.0到约pH 7.4范围内,更优选地在约pH 6.0到pH 7.0范围内。液体医药载剂可包括一种或多种生理学上相容的缓冲液,如磷酸盐缓冲液。所属领域的技术人员可易于确定适用于经肺给药的水溶液的盐水含量和pH。
液体配制物可包括一种或多种悬浮剂,如纤维素衍生物、海藻酸钠、聚乙烯吡咯烷酮、黄芪胶或卵磷脂。液体配制物还可包括一种或多种防腐剂,如对羟基苯甲酸乙酯或对羟基苯甲酸正丙酯。
配制物可使用一种或多种药学上可接受的赋形剂制备,该等赋形剂包括稀释剂、防腐剂、粘合剂、润滑剂、崩解剂、膨胀剂、填充剂、稳定剂和其组合。液体配制物还可含有微量聚合物、表面活性剂或所属领域人员所熟知的其它赋形剂。在此上下文中,“微量”意指不存在赋形剂来可能不利地影响已组装凝胶组合物通过例如循环向靶向组织的递送。
干粉配制物和试剂盒
在一些形式中,胶凝因子、稳定剂以及任选地一种或多种治疗剂、预防剂和诊断剂以干粉形式配制为细粉状固体配制物。干粉组分可储存于独立容器中或以特定比率混合并且储存。在一些实施例中,合适的水性和有机溶剂包括于额外容器中。在一些实施例中,干粉组分、一种或多种溶剂和关于混合并且制备已组装纳米结构的程序的说明书包括于试剂盒中。替代地,稳定的已组装颗粒、纳米颗粒或其块体凝胶通过真空干燥或冷冻干燥来干燥,并且在使用时可添加合适的医药液体载剂以使已组装纳米结构或凝胶组合物再水化并悬浮。
干粉配制物通常通过将一种或多种胶凝因子、稳定剂或活性剂与一种或多种药学上可接受的载剂掺合来制备。医药载剂可包括一种或多种分散剂。医药载剂还可包括一种或多种pH值调节剂或缓冲剂。合适的缓冲剂包括由有机酸和碱制备的有机盐,如柠檬酸钠或抗坏血酸钠。医药载剂还可包括一种或多种盐,如氯化钠或氯化钾。
干粉配制物可悬浮于液体配制物中以形成其已组装颗粒或纳米颗粒,并且使用所属领域中已知的用于递送液体配制物的方法全身性或区域性地给予。
可注射配制物
在一些实施例中,稳定的已组装颗粒被配制成用于肠胃外递送,如注射或输注,呈溶液或悬浮液形式。配制物可通过任何途径如血流给予或向待治疗的器官或组织直接给予。举例来说,肠胃外给药可包括静脉内、皮内、腹膜内、胸膜内、气管内、肌内、皮下、结膜下(subjunctivally)、通过注射和通过输注给予患者。
可使用所属领域中已知的技术制备呈水性组合物形式的肠胃外配制物。通常,这类组合物可按可注射配制物例如溶液或悬浮液的形式、在注射前在添加复原介质时适用于制备溶液或悬浮液的固体形式来制备。
载剂可以是含有例如水、乙醇、一种或多种多元醇(例如甘油、丙二醇和液体聚乙二醇)、油如植物油(例如花生油、玉米油、芝麻油等)和其组合的溶剂或分散介质。
配制物可含有防腐剂以防止微生物生长。合适的防腐剂包括但不限于对羟苯甲酸酯、氯丁醇、苯酚、山梨酸和硫柳汞。配制物还可含有抗氧化剂以防止活性剂降解。
通常将配制物缓冲到pH值3-8以便在复原时肠胃外给予。合适的缓冲液包括但不限于磷酸盐缓冲液、乙酸盐缓冲液和柠檬酸盐缓冲液。
配制物中经常使用水溶性聚合物以便肠胃外给予。合适的水溶性聚合物包括但不限于聚乙烯吡咯烷酮、葡聚糖、羧甲基纤维素以及聚乙二醇。
可通过视需要用一种或多种上文所列的赋形剂将活性化合物以所要量并入适当的溶剂或分散介质中随后过滤灭菌来制备无菌可注射溶液。一般来说,分散液是通过将各种灭菌的胶凝因子、稳定剂和/或活性成分并入含有基础分散介质和来自上文所列的那些的所要其它成分的无菌媒剂中来制备。在无菌粉末用于制备无菌可注射溶液的情况下,优选的制备方法是真空干燥和冷冻干燥技术,其由先前的无菌过滤溶液得到活性成分加上任何额外所需成分的粉末。
防腐剂可用以防止真菌和微生物的生长。合适的抗真菌剂和抗微生物剂包括但不限于苯甲酸、对羟基苯甲酸丁酯、对羟基苯甲酸乙酯、对羟基苯甲酸甲酯、对羟基苯甲酸丙酯、苯甲酸钠、丙酸钠、苯扎氯铵(benzalkonium chloride)、苯甲基过氧化物、苄索氯铵(benzethonium chloride)、苯甲醇、氯化十六烷基吡啶(cetypyridinium chloride)、氯丁醇、苯酚、苯乙醇以及硫柳汞。
合适的口服剂型包括片剂、胶囊、溶液、悬浮液、糖浆以及***片。片剂可使用所属领域中所熟知的压制或模制技术来制备。明胶或非明胶胶囊可使用所属领域中所熟知的技术制备成硬或软胶囊外壳形式,其可以囊封液体、固体以及半固体填充材料。这些优选是包覆肠溶包衣型,以避免当穿过胃时拆解。
赋形剂,包括塑化剂、色素、着色剂、稳定剂和助流剂,还可用于形成包衣组合物以便肠内给药。配制物可如标准参考文献中所描述制备,如“医药剂型片剂(Pharmaceuticaldosage form tablets)”,Liberman等人编(纽约(New York),马塞尔德克公司(MarcelDekker,Inc.),1989)、“雷明顿-药学的科学与实践(Remington-The science andpractice ofpharmacy)”,第20版,马里兰州巴尔的摩的利平科特威廉姆斯和维尔金斯出版社(Lippincott Williams&Wilkins,Baltimore,MD),2000和“医药剂型和药物递送***(Pharmaceutical dosage forms and drug delivery systems)”,第6版,Ansel等人,(宾夕法尼亚州传媒(Media,PA):威廉姆斯与威尔金斯公司(Williams andWilkins),1995)。这些参考文献提供关于用于制备片剂和胶囊以及片剂、胶囊和颗粒的延迟释放剂型的赋形剂、材料、设备以及方法的信息。
III.制备方法
1.制备水凝胶或有机凝胶纳米结构
图1A是显示形成具有纤维形态的块体凝胶的GRAS两亲物的自组装的示意图。图1B显示块体凝胶或颗粒的自组装可具有各种形状,包括胶束、囊泡、薄层或纤维、片材、条带等。一般来说,如图1A中所显示,为形成稳定的自组装凝胶组合物,将溶剂、胶凝因子、稳定剂和任选地待囊封剂添加到容器中以形成混合物。在一些实施例中,混合物可包括一种或多种溶剂(例如,极性溶剂,如二甲亚砜(DMSO)、甲醇、异丙醇、己烷或水)、一种或多种胶凝因子(例如,GRAS胶凝因子)、一种或多种稳定剂和/或一种或多种待囊封剂。可将混合物加热和/或超声处理和/或置于浴中以完全溶解胶凝因子,而形成均质溶液,并且接着将溶液冷却和/或放在不受干扰的位置。在给定时间段后,溶液可转变成粘稠凝胶。当一旦反转容器未观测到重力流时,认为胶凝完成。
为从凝胶中去除未囊封剂,可将可溶解该剂而非凝胶颗粒的水或溶剂添加到凝胶中,并且颗粒分散溶液可反复地涡旋。可去除上清液以提取任何未囊封剂。
当稳定的自组装凝胶组合物不包括溶剂时,胶凝因子可与液体两亲物(例如,维生素衍生的液体两亲物)组合以形成混合物。混合物可包括一种或多种胶凝因子、一种或多种稳定剂和一种或多种液体两亲物。接着将混合物加热/超声处理/置于浴中以形成均质溶液。接着将所得溶液冷却和/或放在不受干扰的位置。在给定时间段后,溶液可转变成粘稠凝胶。
在一些实施例中,一种或多种胶凝因子和任选地待囊封剂可在不存在溶剂下组合以形成混合物。接着将混合物加热/超声处理/置于浴中以形成均质溶液。接着将所得溶液冷却和/或放在不受干扰的位置。在给定时间段后,溶液可转变成粘稠凝胶。
在一些实施例中,为囊封药剂,可将包括一种或多种胶凝因子和一种或多种溶剂的熔融凝胶添加到固体药剂中,添加到溶解于相同的一种或多种溶剂中的药剂中,或添加到溶解或悬浮于凝胶相容溶剂中的药剂中。
在一些实施例中,取决于胶凝因子、稳定剂和/或活性剂的温度敏感性,加热温度可以是40℃(例如,50℃、60℃、70℃、80℃、90℃或100℃)到110℃(例如,100℃、90℃、80℃、70℃、60℃或50℃)。可将这些混合物加热和/或超声处理和/或置于浴中持续一分钟(例如,五分钟、10分钟、15分钟、20分钟或25分钟)到30分钟(25分钟、20分钟、15分钟、10分钟或五分钟)或更长的时长直至所有物质溶解。将溶液冷却到4℃(例如,10℃、20℃或25℃)到37℃(例如,25℃、20℃或10℃)的温度和/或放置15分钟(例如,30分钟、45分钟)到一小时(例如,45分钟、30分钟)的时长。
在一些实施例中,纳米结构(例如,纤维、片材,图1B)的长度和/或宽度可以是数微米(例如,一微米、两微米、三微米、四微米、五微米、十微米、二十微米或二十五微米)或更大。纳米结构可聚集成网络,和/或呈液晶、乳液、纤维状结构或带状形态的形式。当纳米结构呈纤维形式时,纤维的直径可以是约2nm或更大,并且长度可以是数百纳米或更长。在一些实施例中,纤维的长度可以是数微米(例如,一微米、两微米、三微米、四微米、五微米、十微米、二十微米或二十五微米)或更长。
当两亲分子在溶剂中自组装时,胶凝因子分子的疏水部分和亲水部分可相互作用以形成胶凝因子分子的薄层。在一些实施例中,当凝胶是水凝胶时,胶凝因子的疏水部分位于给定薄层的内区域中,并且亲水部分位于薄层的外表面处。在一些实施例中,当凝胶是有机凝胶时,胶凝因子的疏水部分位于给定薄层的外区域中,并且亲水部分位于薄层的内表面处。薄层的宽度可以是约三纳米(例如,约四纳米)到约五纳米(例如,约四纳米),并且长度可以是数微米(例如,一微米、两微米、三微米、四微米、五微米、十微米、二十微米或二十五微米)或更长。数十或数百的这类薄层可束在一起以形成纳米结构,如纳米尺寸宽度(例如,100nm-900nm,长度是数微米或更长)的纤维和片材状结构。
2.待递送剂和稳定剂的囊封
图2A-图2D是概述血清稳定剂在GRAS凝胶中共自组装和囊封以获得血清稳定颗粒的示意图。将低分子量的GRAS或前药胶凝因子、稳定剂和任选地治疗活性剂溶解于水可混溶的有机溶剂中,并且任选地将水或磷酸盐缓冲盐水(PBS)添加到混合物中。胶凝因子可以是胶凝因子、稳定剂和治疗活性剂的总量的至少10摩尔%、20摩尔%、30摩尔%、40摩尔%、50摩尔%、60摩尔%、70摩尔%、80摩尔%或90摩尔%。胶凝因子溶解于溶剂中以达到0.01wt%与50wt%(例如,至多500mg/mL)之间。取决于稳定剂的类型,可将稳定剂添加到胶凝因子、稳定剂和治疗活性剂的总量的3摩尔%、4摩尔%、5摩尔%、6摩尔%、7摩尔%、8摩尔%、9摩尔%、10摩尔%、15摩尔%、20摩尔%、30摩尔%或40摩尔%。对于与胶凝因子共组装的稳定剂,在胶凝因子和稳定剂的总量中,稳定剂的摩尔百分比可在约10摩尔%与约40摩尔%之间,优选在约20摩尔%与约35摩尔%之间,并且最优选是约30摩尔%。
3.加工成颗粒
在一些实施例中,自组装凝胶通过离心(例如,2,000rpm-25,000rpm,持续2分钟-15分钟)、PBS洗涤和/或脉冲超声处理(例如,5kHz-50kHz,10%-50%幅度,持续0.5分钟-10分钟)的重复循环来分离,以提供水可分散性自组装纳米结构或从粒化凝胶中去除未囊封剂。图1C是显示由块体凝胶形成颗粒的示意图。块体凝胶悬浮于水和/或磷酸盐缓冲盐水(“PBS”)中并且超声处理以将块体凝胶破碎成颗粒,该等颗粒保留形成于块体凝胶中的纤维纳米结构。
在一些实施例中,在扫描电子显微术中,当在无水环境如真空干燥的样品中测量时,纳米结构的最小维度(例如,厚度、宽度或直径)可以是2nm或更大(例如,50nm或更大、100nm或更大、150nm或更大、200nm或更大、250nm或更大、300nm或更大、350nm或更大)和/或400nm或更小(例如,350nm或更小、300nm或更小、250nm或更小、200nm或更小、150nm或更小、100nm或更小或500nm或更小);或当通过动态光散射测量流体动力学尺寸时,最小维度可以是10nm、50nm、100nm、200nm、300nm、400nm、500nm或更大。
纳米颗粒的流体动力学直径可在100nm与990nm之间,优选在500nm与900nm之间,并且在血清中在至少两小时的时段内,纳米颗粒维持至少50%、60%、70%或80%的尺寸。
IV.使用方法
针对血液蛋白质造成的拆解,相较于纳米结构或不包括稳定剂的纳米结构,稳定的已组装纳米结构(呈任何形式,包括纳米颗粒)在血液中具有增强的稳定性。组合物可例如通过静脉内、皮内、腹膜内、胸膜内、气管内、肌内、皮下、结膜下注射、通过输注、局部在胃肠外给予或植入。
举例来说,在暴露于水解降解或酶降解时或通过暴露于外部刺激物,稳定的凝胶组合物可按可控方式拆解。凝胶可通过使两亲胶凝因子中不稳定键如酯键、酰胺键、酐键、氨基甲酸酯键、基于磷酸酯的键(例如,磷酸二酯)、二硫化物(-S-S-)、可存在于胶凝因子内的疏水基团与亲水基团之间的酸可裂解基团如-OC(O)-、-C(O)O-或-C=NN-裂解来拆解。不稳定键的实例还描述于例如PCT公开案W02010/033726中。
在一些实施例中,在凝胶拆解时囊封剂可按可控方式从凝胶组合物中释放。举例来说,囊封剂可在一段时间(例如,一天、一周、一月、六个月或一年)内逐渐释放。取决于参数,例如当在生理条件(pH是约7.4并且温度是约37℃)下给予凝胶组合物时,释放可延迟或延长数分钟到数天到数月。
可使用不同参数来控制释放。举例来说,可通过酶浓度和/或温度来控制持续释放。释放可使用高酶浓度例如通过递送到感染区域-其特征在于酶浓度较高-或例如肿瘤或感染区域中的低pH来加速。在一些实施例中,持续释放在无突释的情况下或仅在最小突释的情况下发生。
由于针对蛋白质拆解在血液和其它体液中具有增强的稳定性,并且药物或经囊封活性剂的释放受到控制,因此可使用凝胶组合物或纳米纤维颗粒来以治疗量控制地递送药物或活性剂,持续延长的时间段(例如,一小时、两小时、四小时、十二小时、一天、一周或更长时间)。
在一优选实施例中,稳定的已组装凝胶组合物或纳米纤维颗粒用以将一种或多种活性剂递送于肿瘤组织中,以持续递送化学治疗剂并且甚至被肿瘤细胞吸收。肿瘤细胞产生酯酶,并且发炎组织释放酶,其均病变特异性地降解前药胶凝因子并且释放活性剂。与以自由形式递送的活性剂相比较,在全身给药后,稳定的已组装组合物分配于肿瘤组织中,即,与非肿瘤组织相比在肿瘤组织中积累地更多。
替代地,胶凝因子可施用到生物***并且可原位发生自组装。举例来说,本文所描述的凝胶组合物可施用于骨表面并且凝胶可在骨孔隙内组装。举例来说,加热的凝胶组合物可按溶液形式注射到骨部位,接着可将其冷却到生理温度以组装成凝胶形式。
相较于非稳定的凝胶组合物、已组装纳米结构和呈自由形式的活性剂的递送,稳定的凝胶组合物或纳米纤维颗粒可适用于改进靶向效率、功效、安全性和受益于单剂量、延长作用或组织特异性配制物的依从性。待用稳定的已组装纳米结构治疗的例示性疾病或病症包括但不限于过敏(例如,接触性皮炎)、关节炎、哮喘、癌症、心血管疾病、糖尿病性溃疡、湿疹、感染、发炎、粘膜炎、牙周病、牛皮癣、呼吸路径疾病(例如,肺结核)、血管闭塞、疼痛、移植物抗宿主疾病、口腔溃疡、粘膜炎、细菌病状、病毒病状。
稳定的已组装纳米结构和凝胶组合物也可通过各种已知的区域性递送技术来给予,包括注射、植入、使用气溶胶吸入和局部施用于粘膜,如口或颊表面、鼻或肺道、肠道(口服或经直肠)、***或皮肤。稳定的纳米结构的原位自组装使得组合物以区域方式递送并且使得活性剂以刺激应答方式递送。当肿瘤细胞产生酯酶或发炎组织释放酶时,酶拆解凝胶组合物,其释放活性剂,如消炎剂、抗增生剂或化学治疗剂。药剂释放后,酶浓度降低。未裂解的凝胶组合物保持稳定,直至其它发炎刺激物出现,则“按需求释放”,其中病理环境调节药剂释放的量和时机。在一些实施例中,组合物可适用于释放与组织再生的不同阶段相关的治疗剂。
将通过参考以下非限制性实例进一步理解本发明。
实例
实例1.血液稳定的凝胶的组装。
方法和材料
第一步骤涉及例如在玻璃闪烁瓶中将胶凝因子(棕榈酸抗坏血酸酯)、稳定剂(胆固醇)和待囊封剂(多西他赛、DTX或染料)溶解于适当溶剂中,例如极性溶剂,如二甲亚砜(DMSO)、甲醇、异丙醇、己烷或水。用螺帽密封小瓶并且加热到例如~60℃-80℃,直至物质完全溶解。加热温度可在60℃-80℃范围外,这取决于组成(例如,考虑可能为加热不稳定的或需要更高温度变成一部分凝胶的任何所添加剂)。将小瓶置于稳定表面上并且使其冷却到室温。随后,添加一定量的超纯水并且将密闭小瓶再次加热到~60℃-80℃或任何其它适当的温度,直至所有物质完全溶解。当一旦反转玻璃小瓶未观测到重力流时,在约15分钟-45分钟后发生胶凝。将凝胶悬浮于超纯水中并且以10,000rpm离心10分钟。将离心块再悬浮于超纯水中并且在20kHz、30%幅度下脉冲超声处理2分钟。这可应用于大多数配制物,但可能需要进行微小的调节。幅度和时间可不同。时间可以是30秒-2分钟。可对超声处理进行多次循环。
结果
由棕榈酸抗坏血酸酯(“AP”)-维生素C衍生物-产生颗粒,并且使用胆固醇稳定化。颗粒尺寸和胆固醇与AP的摩尔比显示于图3-图6A和图6B中。研究用扫描电子显微术(SEM)形成的块体凝胶显示了水凝胶形成的纤维结构,其纤维厚度在几十纳米到大约300nm之间,并且纵横比高。用低温TEM观测到来源于块体凝胶的颗粒,并且显示了直径在几十纳米到大约300nm之间并且长度是500-1000nm的纤维形态。评估这种配制物的模型疏水药物多西他赛(DTX)的囊封效率,其通过高性能液相色谱(HPLC)分析确定为30%(图6C)。颗粒显示流体动力学直径是701.4±15nm,多分散指数(pI)是0.2-0.4,并且ζ电位是-47.1±4.2mV。多西他赛的负载效率经确定是0.25%。在表1中列出这些颗粒的生理化学特性。
表1:配制物的生理化学特性(n=3)
参数 | 值 |
流体动力学直径(nm) | 701.4±15 |
多分散性 | 0.3±0.1 |
ζ电位(mV) | -47.1±4 |
DTX的囊封效率(%) | 30±1 |
DTX的负载效率(%) | 0.25 |
如由图3指示,10%血清中的血清稳定性测量显示颗粒稳定至少24小时,其显示流体动力学直径颗粒在血清中在实验时间范围内不显著变化。
图4显示颗粒在磷酸盐缓冲盐水(PBS)中在24小时内具有最小释放(<30%),并且回应于酯酶(200U/mL)稳定地释放。酯酶在肿瘤中过表达。
实例2.针对血清中的拆解用于颗粒的不同稳定剂
方法
在PBS中制备1mg/ml的颗粒悬浮液。在37℃下将1ml颗粒添加到1ml血清。中在t=0小时、0.5小时、1小时、1.5小时、2小时和4小时下通过动态光散射测量血清中颗粒的流体动力学直径。在不同时间点之间,在37℃下培育颗粒。动态光散射中血清单独具有约50nm的尺寸读数。
结果
图5A显示血清中颗粒随时间推移的直径,其中颗粒在不同量的胆固醇存在下由棕榈酸抗坏血酸酯(AP)组装制得。在添加于血清中之前,无胆固醇的AP颗粒的尺寸是800.8±32nm,在添加于血清中时尺寸是约500nm,并且在添加到血清中后0.5小时和其后的时间点下尺寸大体上减小约50nm。减小的尺寸指示不稳定性,即先前已组装结构在血清中拆解。不同于仅AP的颗粒,在添加到血清中之前,由AP和胆固醇以9:1和8:2摩尔比组装制得的颗粒的尺寸分别是724.4±16nm和617±18nm(图5A)。10摩尔%和20摩尔%的胆固醇的存在似乎防止尺寸在血清中持续2小时地大体上减小。在添加到血清中之前,由AP和胆固醇以7:3摩尔比组装制得的颗粒的尺寸是699.8±17nm,并且似乎需要30摩尔%的胆固醇以使颗粒在血清中稳定4小时。
图5B显示以AP:二棕榈酰基磷脂酰基甘油(DPPG)的6:4摩尔比共组装有DPPG的棕榈酸抗坏血酸酯颗粒一般在血清中维持尺寸至少4小时。在添加到血清中之前,这些颗粒的尺寸是389±84nm。这是与无DPPG的AP颗粒相比较,在血清中在短到30分钟内该等AP颗粒的尺寸大体上减小。
图5C显示以AP:多西他赛(DTX)的12:1摩尔比囊封DTX的棕榈酸抗坏血酸酯颗粒一般在血清中维持尺寸至少4小时。DTX似乎是用于已组装颗粒的稳定剂。这是与无DTX的AP颗粒相比较,在血清中在短到30分钟内该等AP颗粒的尺寸大体上减小。
实例3.三甘油单硬脂酸酯颗粒通过胆固醇和DPPG的稳定化
材料和方法
如实例1中制备凝胶和颗粒。添加胆固醇或DPPG作为稳定剂。
结果
图6A是显示胆固醇(Chol)充当三甘油单硬脂酸酯(TG-18)颗粒的稳定剂、并且有助于防止其在50%血清中在37℃下聚集的图式。TG-18颗粒不同于AP颗粒,其往往会在血清中聚集,导致其尺寸随时间推移而增加。这一聚集通过添加40摩尔%的胆固醇来防止。
图6B是显示DPPG充当三甘油单硬脂酸酯(TG-18)颗粒的稳定剂、并且有助于防止其在50%血清中在37℃下聚集的图式。TG-18颗粒不同于AP颗粒,其往往会在血清中聚集,导致其尺寸随时间推移而增加。这一聚集通过添加40摩尔%的DPPG来防止。
图6C是显示多西他赛(DTX)不使三甘油单硬脂酸酯(TG-18)颗粒稳定、并且不有助于防止其在50%血清中在37℃下聚集的图式。TG-18颗粒不同于AP颗粒,其往往会在血清中聚集,导致其尺寸随时间推移而增加。这一聚集不会通过添加8摩尔%的DTX得到防止。
实例4.脱水山梨糖醇单硬脂酸酯颗粒通过胆固醇和DPPG的稳定化
材料和方法
如实例1中制备凝胶和颗粒。添加胆固醇或DPPG作为稳定剂。
结果
图7A是显示胆固醇(Chol)部分地使脱水山梨糖醇单硬脂酸酯(SMS)颗粒在50%血清中在37℃下稳定的图式。在血清中SMS颗粒往往会显示即刻的拆解,导致其尺寸急剧并且快速地减小,并且这随后是其聚集,导致其尺寸随时间推移而增加。在时间t=0下,SMS颗粒的尺寸从585nm(PBS中的尺寸)降到160nm,指示其在血清中拆解。随后,由于聚集,尺寸增加。添加40摩尔%的chol防止最初的拆解但不防止后续的聚集。
图7B是显示DPPG部分地使脱水山梨糖醇单硬脂酸酯(SMS)颗粒在50%血清中在37℃下稳定的图式。在血清中SMS颗粒往往会显示即刻的拆解,导致其尺寸急剧并且快速地减小,并且这随后是其聚集,导致其尺寸随时间推移而增加。在时间t=0下,SMS颗粒的尺寸从585nm(PBS中的尺寸)降到160nm,指示其在血清中拆解。随后,由于聚集,尺寸增加。添加40摩尔%的DPPG防止最初的拆解但不防止后续的聚集。
实例5.对体外癌细胞代谢的抑制、递送化学治疗剂的协同功效和体内肿瘤组织中的分配.
材料和方法
以与实例1中所显示相同的方法制备颗粒。
在体外在***癌细胞PC3和LNCaP中研究纳米纤维细胞毒性。
在Balb/c小鼠中使用皮下4T3鼠乳癌模型进行颗粒的体内生物分布研究。将小鼠分成三个组,其中每组三只小鼠-无处理的对照组、用染料(DiR)负载的棕榈酸抗坏血酸酯颗粒的测试组和自由染料的另一测试组。
结果
图8A是显示以下的代谢活性%的线图:用一系列浓度(μM)的维生素C溶液培育48小时(“Vit C 48h”,黑色正方形)、或用稳定的维生素C衍生颗粒培育24小时或48小时(分别是“Vit C颗粒24h”(灰色正方形)和“Vit C颗粒48h”(三角形))的PC3(PC-3)人类***癌细胞。图8B是显示以下的代谢活性%的线图:用Vit C培育48小时(黑色方形)、用Vit C颗粒培育24小时(灰色方形)和用Vit C颗粒培育48小时(三角形)的LNCaP雄激素敏感性人类***腺癌细胞。
图9A和图9B是显示当用一系列浓度(μM)的稳定的维生素C衍生颗粒(“Vit C颗粒”,灰色方形)、自由多西他赛(“自由DTX”,菱形)或囊封多西他赛的稳定的维生素C衍生颗粒(“DTX负载的Vit C颗粒”,三角形)培育时,PC3细胞的代谢活性%(图9A)和LNCaP细胞的代谢活性%(图9B)的线图。
相较于维生素C溶液,使用棕榈酸抗坏血酸酯作为胶凝因子,释放抗坏血酸即维生素C的颗粒显示改进的抗癌功效。发现用于***癌细胞的维生素C颗粒的半数最大抑制浓度(IC50)在40μM与60μM之间的范围内。然而,维生素C溶液在这一浓度下并不显示任何作用。这可具有朝着减少用于癌症患者的维生素C治疗剂量的方向的含义。
在抑制或杀死***癌细胞中,负载有化学治疗剂、多西他赛(DTX)的棕榈酸抗坏血酸酯颗粒在DTX与维生素C之间展现增强的抗癌作用。这些颗粒的IC50值经确定对于PC-3细胞和LNCaP细胞分别为0.07μM和0.13μM;其比自由DTX的IC50小得多,该自由DTX的IC50对于PC-3细胞和LNCaP细胞分别是0.62μM和3.6μM。这指示颗粒通过降低为半部最大抑制必需的浓度而显著增加囊封药物的有效性。表2显示基于Chou Talaly组合指数(CombinationIndex)的组合指数(combination indice)小于一,指示在维生素C与囊封化学治疗剂之间的协同效应。
表2:癌细胞系中配制物的IC50(μm)和组合指数(n=3)
认为当囊封剂与所包覆、共组装或作为胶凝因子的其它剂如维生素K或其前药组合时,治疗功效将增强。
图10是显示对于对照(未处理)小鼠和给予自由染料或囊封该染料的稳定的维生素C衍生颗粒的小鼠,在给药后3小时、8小时和12小时,小鼠肿瘤组织中染料(DiR)的归一化荧光随时间(小时)推移的条形图。图10显示相较于对照(未注射)和使用自由染料的注射,如从肿瘤组织的荧光成像中定量,在给药后不同小时下,颗粒在肿瘤组织中的积聚增加。
图11A和图11B是显示患有乳癌的小鼠中呈自由形式或负载于稳定的维生素C衍生颗粒中的给药后染料的组织分布的条形图。图11A显示染料在不同组织中的荧光强度。图11B显示肿瘤中的荧光与肝脏中的荧光的比率。图11A和图11B显示与自由染料相比,对于颗粒,肿瘤中的积聚与肝脏中的积聚的比率显著更高。
Claims (33)
1.一种自组装有机凝胶或水凝胶组合物,包含
一种或多种选自烷酸抗坏血酸酯及三甘油单烷酸酯的低分子量的两亲胶凝因子,其分子量小于2,500 Da,其通过非共价相互作用自组装,和
一种或多种稳定剂,其选自固醇和磷脂,
其中所述一种或多种低分子量的胶凝因子和所述一种或多种稳定剂以呈纳米结构形式共组装,
其中:
当所述一种或多种低分子量的胶凝因子是烷酸抗坏血酸酯以及所述一种或多种稳定剂是固醇,所述一种或多种稳定剂是所述有机凝胶或水凝胶组合物的至少10摩尔%;
当所述一种或多种低分子量的胶凝因子是烷酸抗坏血酸酯以及所述一种或多种稳定剂是磷脂,所述一种或多种稳定剂是所述有机凝胶或水凝胶组合物的至少40摩尔%,以及
当所述一种或多种低分子量的胶凝因子是三甘油单烷酸酯以及所述一种或多种稳定剂是磷脂,所述一种或多种稳定剂是所述有机凝胶或水凝胶组合物的至少40摩尔%。
2.根据权利要求1所述的组合物,其中在37℃下在含血清蛋白的磷酸盐缓冲盐水存在下,所述组合物维持其至少50%的尺寸,并且至少30分钟不聚集到为相对于所述组合物在暴露于血清蛋白之前的尺寸的两倍。
3.根据权利要求1所述的组合物,其中所述一种或多种低分子量的两亲胶凝因子是符合美国食品和药物管理局(U.S. Food and Drug Administration)为普遍认为安全(GRAS)化合物要求的化合物。
4.根据权利要求1所述的组合物,其中所述一种或多种低分子量的两亲胶凝因子是酶可裂解的。
5.根据权利要求1所述的组合物,其中所述一种或多种稳定剂对已组装结构赋予硬度、增加其充填密度和/或增强其强度,进而改变相转变过程和转变温度,和/或调节其块体凝胶或颗粒的表面特性以减少或防止蛋白质粘着或积聚。
6.根据权利要求1所述的组合物,其中所述烷酸抗坏血酸酯选自由以下所组成的组:棕榈酸抗坏血酸酯、癸酸抗坏血酸酯、月桂酸抗坏血酸酯、辛酸抗坏血酸酯、肉豆蔻酸抗坏血酸酯和油酸抗坏血酸酯。
7.根据权利要求1所述的组合物,其中所述三甘油单烷酸酯选自由以下所组成的组:三甘油单棕榈酸酯、三甘油单癸酸酯、三甘油单月桂酸酯、三甘油单辛酸酯、三甘油单肉豆蔻酸酯、三甘油单硬脂酸酯和三甘油单油酸酯。
8.根据权利要求1所述的组合物,其中所述固醇选自由以下所组成的组:胆固醇、皮质类固醇、以及植物固醇。
9.根据权利要求1所述的组合物,其中所述固醇选自由以下所组成的组:醛固酮、雄酮、睾酮、***、麦角钙化醇、***-17α、***-17β、胆酸、皮质酮、雌三醇、石胆酸、孕酮、胆钙化醇、皮质醇、可的松(cortisone)、乙酸可的松、乙酸皮质醇、以及脱氧皮质酮和雌酮。
10.根据权利要求1所述的组合物,其中所述固醇选自由以下所组成的组:菜油固醇、豆固醇、菜籽固醇、麦角固醇(ergocasterol)、维生素D、谷固醇、以及岩藻固醇。
11.根据权利要求1所述的组合物,其中所述固醇是羊毛固醇。
12.根据权利要求10所述的组合物,其中所述谷固醇是β-谷固醇。
13.根据权利要求8所述的组合物,其中所述皮质类固醇是二氢胆固醇。
14.根据权利要求1所述的组合物,其中所述固醇是胆固醇。
15.根据权利要求1所述的组合物,其中所述磷脂选自由以下所组成的组:二棕榈酰基磷脂酰基甘油、二棕榈酰基磷脂酰基胆碱和二硬脂酰基磷脂酰基胆碱。
16.根据权利要求1所述的组合物,其中所述磷脂是二棕榈酰基磷脂酰基甘油。
17.根据权利要求1所述的组合物,其中所述纳米结构和/或颗粒包含纤维、薄层状结构、胶束结构、囊状结构、片材或带状结构。
18.根据权利要求1所述的组合物,其中所述水凝胶或有机凝胶呈颗粒形式。
19.根据权利要求1所述的组合物,进一步包含一种或多种治疗剂、预防剂或诊断剂。
20.根据权利要求19所述的组合物,其中所述一种或多种治疗剂、预防剂或诊断剂是化学治疗剂。
21.根据权利要求20所述的组合物,其中所述化学治疗剂是多西他赛。
22.根据权利要求1所述的组合物,进一步包含一种或多种医药赋形剂。
23.一种试剂盒,包含根据权利要求1所述的组合物的剂量单位。
24.根据权利要求23所述的试剂盒,其中所述剂量单位包含用于无水组分的一个或多个容器和用于液体组分的一个或多个容器,其混合在一起形成自组装组合物。
25.一种制备如由权利要求1所定义的血清稳定的自组装有机凝胶或水凝胶组合物的方法,所述方法包含:
组合分子量小于2,500 Da的一种或多种选自烷酸抗坏血酸酯及三甘油单烷酸酯的低分子量两亲胶凝因子、如由权利要求1-22中任一项权利要求所定义的一种或多种稳定剂和任选地治疗剂、预防剂或诊断剂,以形成包含纳米结构的有机凝胶或水凝胶。
26.根据权利要求25所述的方法,包含向所述有机凝胶或水凝胶添加治疗剂、预防剂或诊断剂。
27.根据权利要求25所述的方法,进一步包含以物理方式将所述有机凝胶或水凝胶分离成颗粒。
28.根据权利要求25所述的方法,包含通过混合或加热将所述一种或多种胶凝因子添加于极性溶剂中,
使所述混合物冷却,
通过混合或加热将所述混合物溶解于水中,其中发生胶凝,和
任选地通过离心去除未组装剂和未囊封剂。
29.一种从根据权利要求1所述的有机凝胶或水凝胶中分离包含或不包含稳定剂的颗粒的方法,所述方法包含:
将水或溶剂或溶液添加到所述有机凝胶或水凝胶中,
快速地混合,
离心,和
去除上清液以分离所述有机凝胶或水凝胶的颗粒。
30.根据权利要求29所述的方法,包含将水溶液或溶剂添加到所述离心颗粒中,并且在存在或不存在脉冲超声处理下通过混合2分钟,将所述颗粒分散于水溶液中。
31.一种根据权利要求19所述的组合物在制备用于向个体递送治疗剂、预防剂或诊断剂的药剂中的应用。
32.根据权利要求31所述的应用,其中所述组合物是静脉内给予。
33.根据权利要求31所述的应用,其中相较于以自由形式或无稳定剂的自组装水凝胶或有机凝胶形式递送的药剂,所述组合物在肿瘤中积聚。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562239211P | 2015-10-08 | 2015-10-08 | |
US62/239,211 | 2015-10-08 | ||
PCT/US2016/056070 WO2017062818A1 (en) | 2015-10-08 | 2016-10-07 | Stabilized assembled nanostructures for delivery of encapsulated agents |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108289833A CN108289833A (zh) | 2018-07-17 |
CN108289833B true CN108289833B (zh) | 2022-01-25 |
Family
ID=57206400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680066453.1A Active CN108289833B (zh) | 2015-10-08 | 2016-10-07 | 用于递送囊封剂的稳定的已组装纳米结构 |
Country Status (7)
Country | Link |
---|---|
US (2) | US9962339B2 (zh) |
EP (1) | EP3359128A1 (zh) |
JP (2) | JP7121654B2 (zh) |
CN (1) | CN108289833B (zh) |
AU (1) | AU2016335846B2 (zh) |
CA (1) | CA3001423C (zh) |
WO (1) | WO2017062818A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110229565A1 (en) | 2008-09-17 | 2011-09-22 | Karp Jeffrey M | Drug Delivery Composition Comprising a Self-Assembled Gelator |
EP3412279B1 (en) | 2010-09-24 | 2021-02-17 | The Brigham and Women's Hospital, Inc. | Nanostructured gels capable of controlled release of encapsulated agents |
WO2017062818A1 (en) * | 2015-10-08 | 2017-04-13 | The Brigham And Women's Hospital, Inc. | Stabilized assembled nanostructures for delivery of encapsulated agents |
US11020410B2 (en) | 2017-02-03 | 2021-06-01 | The Brigham And Women's Hospital, Inc. | Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof |
EP3621594A1 (en) * | 2017-05-08 | 2020-03-18 | Alivio Therapeutics, Inc. | Formulation of nanostructured gels for increased agent loading and adhesion |
CN107334745A (zh) * | 2017-05-22 | 2017-11-10 | 中国人民解放军第三军医大学第三附属医院 | 多功能纳米药物载体和紫杉醇类脂质纳米粒及其制备方法 |
CN113825495A (zh) * | 2018-10-11 | 2021-12-21 | 阿利维奥治疗学股份有限公司 | 用于智能释放的不可注射水凝胶调配物 |
CN114903871A (zh) * | 2022-05-09 | 2022-08-16 | 郑州大学第一附属医院 | 负载雷公藤甲素的抗炎纳米组合物和制备方法及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1301147A (zh) * | 1998-04-30 | 2001-06-27 | Ucb公司 | 可用于牙周的胶凝药物组合物 |
CN102316902A (zh) * | 2009-02-20 | 2012-01-11 | to-BBB控股股份有限公司 | 基于谷胱甘肽的药物递送*** |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2417494A1 (fr) | 1978-02-16 | 1979-09-14 | Bottu | Nouvelles compositions analgesiques et antipyretiques contenant un derive de paracetamol |
CA2070061C (en) | 1991-06-07 | 2004-02-10 | Shigeyuki Takama | Physiologically active polypeptide-containing pharmaceutical composition |
GB9403857D0 (en) | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
CA2212300A1 (en) | 1997-08-04 | 1999-02-04 | Abdellatif Chenite | In vitro or in vivo gelfying chitosan and therapeutic uses thereof |
FR2794998B1 (fr) | 1999-06-21 | 2001-07-27 | Oreal | Organogels et leurs utilisations notamment cosmetiques |
US20050084470A1 (en) | 2003-10-15 | 2005-04-21 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Skin care and cleansing compositions containing oil seed product |
DE602004031301D1 (de) | 2003-11-12 | 2011-03-17 | Applied Nanosystems Bv | Nichtsymmetrisches geliermittel |
US7749485B2 (en) | 2004-06-03 | 2010-07-06 | Bracco Research S.A. | Liposomal assembly for therapeutic and/or diagnostic use |
FR2871701B1 (fr) | 2004-06-21 | 2006-09-22 | Centre Nat Rech Scient Cnrse | Biomateriaux bioactifs pour le relarguage controle de principes actifs |
US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
EP1800694A1 (en) | 2005-12-23 | 2007-06-27 | Applied NanoSystems B.V. | Controlled release gels |
US8968784B2 (en) | 2006-05-22 | 2015-03-03 | Research Foundation Of The City University Of New York | Method for preparing hydro/organo gelators from disaccharide sugars by biocatalysis and their use in enzyme-triggered drug delivery |
WO2009029543A1 (en) | 2007-08-24 | 2009-03-05 | Aegis Therapeutics, Llc | Controlled release formulations |
US20110229565A1 (en) | 2008-09-17 | 2011-09-22 | Karp Jeffrey M | Drug Delivery Composition Comprising a Self-Assembled Gelator |
EP2361640A1 (en) | 2010-02-25 | 2011-08-31 | Université de Liège | Cell cultivation in chitosan alginate hydrogel beads |
EP3412279B1 (en) * | 2010-09-24 | 2021-02-17 | The Brigham and Women's Hospital, Inc. | Nanostructured gels capable of controlled release of encapsulated agents |
GB201020193D0 (en) | 2010-11-29 | 2011-01-12 | Biotec Pharmacon Asa | Glucan compositions |
CN108635240B (zh) * | 2012-06-25 | 2021-09-14 | 日产化学工业株式会社 | 分散液及水凝胶形成方法 |
CA2886109A1 (en) | 2012-12-07 | 2014-06-12 | Kansas State University Research Foundation | Peptide-albumin hydrogel properties and its applications |
SG11201507370TA (en) | 2013-03-14 | 2015-10-29 | Massachusetts Inst Technology | Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies |
WO2017062818A1 (en) * | 2015-10-08 | 2017-04-13 | The Brigham And Women's Hospital, Inc. | Stabilized assembled nanostructures for delivery of encapsulated agents |
-
2016
- 2016-10-07 WO PCT/US2016/056070 patent/WO2017062818A1/en active Application Filing
- 2016-10-07 US US15/288,816 patent/US9962339B2/en active Active
- 2016-10-07 CN CN201680066453.1A patent/CN108289833B/zh active Active
- 2016-10-07 CA CA3001423A patent/CA3001423C/en active Active
- 2016-10-07 JP JP2018517604A patent/JP7121654B2/ja active Active
- 2016-10-07 AU AU2016335846A patent/AU2016335846B2/en active Active
- 2016-10-07 EP EP16787639.0A patent/EP3359128A1/en active Pending
-
2018
- 2018-04-27 US US15/965,499 patent/US10300023B1/en active Active
-
2022
- 2022-05-19 JP JP2022082290A patent/JP2022103380A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1301147A (zh) * | 1998-04-30 | 2001-06-27 | Ucb公司 | 可用于牙周的胶凝药物组合物 |
CN102316902A (zh) * | 2009-02-20 | 2012-01-11 | to-BBB控股股份有限公司 | 基于谷胱甘肽的药物递送*** |
Non-Patent Citations (3)
Title |
---|
Ascorbyl palmitate vesicles (Aspasomes): formation,characterization and applications;D. Gopinath等;《International Journal of Pharmaceutics 》;20041231;第271卷;第95-113页 * |
Degradation of phosphatidylcholine in liposomes containing carboplatin in dependence on composition and storage conditions;B. Pietzyk;《International Journal of Pharmaceutics 》;20001231;第196卷;第215-218页 * |
Nanolipid carrier-based thermoreversible gel for localized delivery of docetaxel to breast cancer;Tanya Vohra等;《Cancer Nano》;20130316(第4期);第1-12页 * |
Also Published As
Publication number | Publication date |
---|---|
JP2022103380A (ja) | 2022-07-07 |
EP3359128A1 (en) | 2018-08-15 |
JP2018530561A (ja) | 2018-10-18 |
JP7121654B2 (ja) | 2022-08-18 |
AU2016335846A1 (en) | 2018-05-10 |
CN108289833A (zh) | 2018-07-17 |
WO2017062818A1 (en) | 2017-04-13 |
US10300023B1 (en) | 2019-05-28 |
CA3001423C (en) | 2021-05-04 |
US9962339B2 (en) | 2018-05-08 |
AU2016335846B2 (en) | 2019-04-04 |
US20170100342A1 (en) | 2017-04-13 |
CA3001423A1 (en) | 2017-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108289833B (zh) | 用于递送囊封剂的稳定的已组装纳米结构 | |
Yang et al. | Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer | |
Fang et al. | Nanostructured lipid carriers (NLCs) for drug delivery and targeting | |
JP6175237B2 (ja) | コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法 | |
US20200246278A1 (en) | Injectable diethylstilbestrol nanosuspension formulation | |
Sheu et al. | Codelivery of doxorubicin-containing thermosensitive hydrogels incorporated with docetaxel-loaded mixed micelles enhances local cancer therapy | |
US9655848B2 (en) | Liposomes for in-vivo delivery | |
Yuan et al. | A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity | |
CA3062885C (en) | Self-assembled gels for controlled delivery of biologics and labile agents | |
JP2015098493A (ja) | ビンカアルカロイド含有治療用ポリマーナノ粒子並びにその製造方法及び使用方法 | |
Wei et al. | Janus nanogels of PEGylated Taxol and PLGA–PEG–PLGA copolymer for cancer therapy | |
US20190046446A1 (en) | Apo-e modified lipid nanoparticles for drug delivery to targeted tissues and therapeutic methods | |
JP2017502985A (ja) | 修飾シクロデキストリン複合体をカプセル化するリポソーム組成物およびその使用 | |
Manjappa et al. | Is an alternative drug delivery system needed for docetaxel? The role of controlling epimerization in formulations and beyond | |
US20140105829A1 (en) | Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same | |
Wen et al. | Polymer‐stabilized micelles reduce the drug rapid clearance in vivo | |
US8859001B2 (en) | Fenoldopam formulations and pro-drug derivatives | |
Dehghan et al. | Enhanced in vitro and in vivo anticancer activity through the development of Sunitinib-Loaded nanoniosomes with controlled release and improved uptake | |
JP2023168587A (ja) | 増大した薬剤負荷および接着のためのナノ構造化ゲルの製剤 | |
US20190328903A1 (en) | Polymer nanoparticle composition for plasmid dna delivery, and preparation method therefor | |
WO2019028457A2 (en) | FORMULATION OF NANOSUSPENSION OF DIETHYLSTILBESTROL INJECTABLE | |
Abdoullateef et al. | Nanoencapsulation of general anaesthetics | |
DANDAGI et al. | Indian Journal of Novel Drug Delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |